

Meeting abstract

Open Access

SAP102, a novel interaction partner of the A_{2A} adenosine receptor

Ingrid Gsandtner, Nicole Ferstl, Michael Freissmuth and Jürgen Zezula*

Address: Department of Pharmacology, Medical University of Vienna, Austria

Email: Jürgen Zezula* - juergen.zezula@meduniwien.ac.at

* Corresponding author

from 13th Scientific Symposium of the Austrian Pharmacological Society (APHAR). Joint Meeting with the Austrian Society of Toxicology (ASTOX) and the Hungarian Society for Experimental and Clinical Pharmacology (MFT)
Vienna, Austria. 22–24 November 2007

Published: 14 November 2007

BMC Pharmacology 2007, 7(Suppl 2):A5 doi:10.1186/1471-2210-7-S2-A5

This abstract is available from: <http://www.biomedcentral.com/1471-2210/7/S2/A5>

© 2007 Gsandtner et al; licensee BioMed Central Ltd.

Adenosine receptors are G protein-coupled receptors and are implicated in several neurological and psychiatric disorders such as Parkinson's disease, schizophrenia and Alzheimer's disease. These receptors can be distinguished by their affinity for adenosine analogues and by their preferred signal transduction pathway. The A_{2A} receptor has an unusually long intracellular carboxyl terminus. We identified SAP102 (synapse-associated protein of 102 kDa) as a novel interaction partner of the adenosine A_{2A} receptor. SAP102 belongs to the family of MAGUK (membrane-associated guanylate kinase-like domain) proteins. These proteins have an established function in synaptic organization, which is reflected by their modular structure. Our data demonstrate that the A_{2A} receptor binds to C-terminal domains of SAP102. Furthermore we identified the responsible binding motif consisting of 5 amino acids in the receptor's C-terminus. In hippocampal neurons we observed a co-localization of both proteins especially in punctuate structures along the neurite extensions that presumably represented dendritic spines. In the next step we will use several fluorescence-based techniques in order to investigate the influence of SAP102 on the mobility and targeting of the A_{2A} receptor.